Drug intelligence / Profile preview

MT-301

Development stage: Discontinued
Lead developer: Myeloid Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

MT-301 is an investigational immunologic cytotoxic cell therapy being developed by Myeloid Therapeutics for oncology indications. It is described as a myeloid cell–based immunotherapy engineered to exert cytotoxic activity against tumor cells, leveraging innate immune effector functions rather than conventional small-molecule or antibody mechanisms.[13] Development has been discontinued, and detailed public information on its specific target antigen, construct design, and clinical data is limited.

Beyond the preview

Go deeper on MT-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT-301.

Explore the full profile